PTP4A3 and acute myeloid leukemia: Our previous reports demonstrate that PRL3 antibody therapy can inhibit PRL3+ tumors in multiple animal models using cancer cell lines derived from different origins, including ovarian, colorectal, melanoma, lung, AML, and gastric tissues (Supplementary Table 1).